SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Hank who wrote (3917)5/5/1998 10:21:00 AM
From: Linda Kaplan  Read Replies (1) of 7041
 
Hank: I posted the WSJ article yesterday on the faster-acting form of Viagra that is being developed.

While it will take some long time to be ready, but so will Vasomax, and PFE has the market share and the more effective product.

So, yes, I think it should knock any potential advantage to Vasomax (that we have heard about) out of the water.

PFE put billions into development of Viagra. I think they will continue to improve it, while Vasomax is still struggling to file their application with the FDA. It would be difficult for Vasomax to develop market share by the time it is approved, if it ever is approved.

Linda
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext